Charles River Laboratories International, Inc.
CRL
$291.76
$9.423.34%
NYSE
| 06/27/2026 | 03/28/2026 | 12/27/2025 | 09/27/2025 | 06/28/2025 | |
|---|---|---|---|---|---|
| Net Income | -255.68% | -839.36% | -750.08% | -119.42% | -115.18% |
| Total Depreciation and Amortization | -12.77% | -10.08% | -8.39% | -30.14% | -5.79% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 30.34% | 30.50% | 36.46% | 3,551.34% | 13,312.31% |
| Change in Net Operating Assets | -351.82% | -589.69% | 146.43% | -169.54% | 321.87% |
| Cash from Operations | -26.07% | -21.81% | 0.42% | -5.86% | 5.02% |
| Capital Expenditure | -1.24% | -1.21% | 5.93% | 12.67% | 20.52% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -7,291.97% | -- | 100.00% | 100.00% |
| Divestitures | 912.34% | 244.57% | -- | -- | -- |
| Other Investing Activities | -135.64% | -207.72% | -14.61% | 80.35% | 121.43% |
| Cash from Investing | -180.87% | -179.18% | 14.59% | 52.71% | 61.29% |
| Total Debt Issued | 17.31% | 43.99% | 13.49% | -17.21% | 5.50% |
| Total Debt Repaid | 13.38% | -15.17% | 9.67% | 19.51% | 8.40% |
| Issuance of Common Stock | 50.71% | -18.37% | -97.01% | -97.35% | -95.19% |
| Repurchase of Common Stock | 29.76% | 53.38% | -202.64% | -202.63% | -2,401.87% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 67.03% | 37.32% | -26.57% | -33.21% | -90.40% |
| Cash from Financing | 96.52% | 87.60% | 2.58% | -59.54% | -100.67% |
| Foreign Exchange rate Adjustments | -88.83% | 487.52% | 207.75% | -83.32% | 334.72% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,394.67% | 68.61% | 113.21% | -105.26% | 113.45% |